XERS XP-8121 enters Phase 3, targeting 2030 FDA approval
XP-8121, a once-weekly injectable levothyroxine, will enter Phase 3 trials by year-end 2026. The program targets FDA approval and launch in 2030, aiming for $1—3B peak net revenue.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.